Alnylam Pharmaceuticals, Inc. (ALNY): Here’s What The Smart Money Thinks
Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the right investment to pursue these days? Hedge funds are taking a bullish view.
Posts Tagged ‘NASDAQ:IMGN’
Seattle Genetics, Inc. (SGEN), Celldex Therapeutics, Inc. (CLDX): This Company Has Potential to Grow
Cancer is the target of a number of different biotech companies. Out of this lot, I consider Seattle Genetics, Inc. (NASDAQ:SGEN) to be one of the star performers.
Immunomedics, Inc. (IMMU), ImmunoGen, Inc. (IMGN): Should You Invest in These Cancer Treatment Biotechs?
Today, cancer is the second leading cause of death in the United States, accounting for nearly a quarter of all deaths in the country.
Seattle Genetics, Inc. (SGEN): A Billion-Dollar Anticancer Technology in the Making
Anticancer drugs typically damage normal cells as well as cancer cells.
ImmunoGen, Inc. (IMGN), Seattle Genetics, Inc. (SGEN), Celldex Therapeutics, Inc. (CLDX): A Trio of Cancer Immunotherapy Innovators
The cancer world has been abuzz after an exciting ASCO conference. Bristol Myers Squibb Co.
Is Nektar Therapeutics (NKTR) Going to Burn These Hedge Funds?
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds' portfolio at the end of March.
Synta Pharmaceuticals Corp. (SNTA), VeriFone Systems Inc (PAY): 5 of Last Week’s Biggest Losers
Let's start with Synta Pharmaceuticals Corp. (NASDAQ:SNTA).
This Metric Says You Are Smart to Sell ImmunoGen, Inc. (IMGN)
Is ImmunoGen, Inc. (NASDAQ:IMGN) an excellent investment now? Prominent investors are in a bearish mood.
ImmunoGen, Inc. (IMGN), AEterna Zentaris Inc. (USA) (AEZS) – Tackling Cancer: Your Best Investing Ideas
Over the past three months, we've taken a deep dive into the 12 cancer types most likely to be diagnosed in the U.S.
Myriad Genetics, Inc. (MYGN), Roche Holding Ltd. (ROG): Angelina Jolie’s Selfless Act Heightens Breast Cancer Awareness
I admit to not being a big fan of many of her movies -- possibly the only man on the planet who will admit so -- but there's little denying that movie sensation Angelina Jolie...
Hedge Funds Are Selling ImmunoGen, Inc. (IMGN)
At the moment, there are dozens of methods market participants can use to monitor publicly traded companies. Some of the best are hedge fund and insider trading sentiment.
Sarepta Therapeutics Inc (SRPT): FDA Says, “Call Me Maybe”
A lot has been written this week -- at The Fool and elsewhere -- about Sarepta Therapeutics Inc (NASDAQ:SRPT)' update on its meeting with the Food and Drug Administration.
Acorda Therapeutics Inc (ACOR): Insiders Are Dumping, Should You?
Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds' portfolio at the end of the fourth quarter of 2012.
Pfizer Inc. (PFE) & More…a ‘Breakthrough’ May Be on the Way for Breast Cancer Patients
The process of developing a drug from start to finish is incredibly arduous, usually involves around $1 billion in costs, and can take upwards of a decade to complete.
Tackling Cancer: Breast Cancer’s Biggest Current & Upcoming Players – Roche Holding Ltd. (ADR) (RHHBY), AstraZeneca plc (ADR) (AZN), ImmunoGen, Inc. (IMGN)
As I noted two weeks ago, cancer statistics are both staggering and disappointing.
This FDA Approval Is Actually a Big Deal: Dendreon Corporation (DNDN)
As we've learned in recent years, getting an approval from the Food and Drug Administration is only half the battle.
This Week in Biotech: VIVUS, Inc. (VVUS), Roche Holdings Ltd-Spons Adr (RHHBY)
With the SPDR S&P Biotech Index up 25% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
